Finance

Lists
Q2 2026 earnings • released • EPS beat +15.33% • Revenue beat +1.39%
See results
DXCM:NASDAQ
DexCom Inc
$86.87
+4.10%
(+3.42) 1D
Aug 3, 3:06:22 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DXCM...
Open
$85.25
High
$87.62
Low
$83.50
Mkt. cap
32.78B
Avg. vol.
4.96M
Volume
5.33M
P/E ratio
34.46
52-wk high
$87.62
52-wk low
$54.11
EPS
$2.52
Beta
1.45
Shares outstanding
377.36M
No. of employees
11K
Open
$85.25
High
$87.62
Low
$83.50
Mkt. cap
32.78B
Avg. vol.
4.96M
Volume
5.33M
P/E ratio
34.46
52-wk high
$87.62
52-wk low
$54.11
EPS
$2.52
Beta
1.45
Shares outstanding
377.36M
No. of employees
11K
News stories
From sources across the web
Profile
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S., and manufacturing facilities in Mesa, Arizona, U.S.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. Wikipedia
About DexCom Inc
CEOKevin R. Sayer
Employees11K
Founded1999
HeadquartersSan Diego, California, United States
SectorMedical device
Websitedexcom.com
Analyst ratings
Based on 23 analysts giving stock ratings to DXCM in the past 3 months
Strong buy
Buy
21
Hold
1
Sell
1
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for DXCM in the last 3 months.
Highest
Current $86.87
$112.00 (+28.93%)
Average
$90.05 (+3.66%)
Lowest
$64.00 (-26.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
William Plovanic
Canaccord Genuity
Buy
Reiterated
$90.00
+3.6%
08/03/2026
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
07/31/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
07/31/2026
Kieran Ryan
Deutsche Bank
Buy
Reiterated
$92.00
+5.9%
07/31/2026
Kendall Au
RBC Capital
Buy
Maintained
$90.00
+3.6%
07/31/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$90.00
+3.6%
07/31/2026
Jayson Bedford
Raymond James
Buy
Maintained
$94.00
+8.2%
07/31/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$82.00
-5.6%
07/31/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$93.00
+7.1%
07/31/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$95.00
+9.4%
07/31/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$95.00
+9.4%
07/31/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$90.00
+3.6%
07/31/2026
Robbie Marcus
J.P. Morgan
Hold
Reiterated
$82.00
-5.6%
07/31/2026
Jeff Johnson
Robert W. Baird
Buy
Maintained
$105.00
+20.9%
07/31/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
$95.00
+9.4%
07/31/2026
Joanne Wuensch
Citi
Buy
Reiterated
$88.00
+1.3%
07/31/2026
Marie Thibault
BTIG
Buy
Reiterated
$90.00
+3.6%
07/31/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$95.00
+9.4%
07/30/2026
Danielle Antalffy
UBS
Buy
Maintained
$96.00
+10.5%
07/28/2026
Unknown Analyst
Deutsche Bank
Buy
Initiated
$86.00
-1%
06/25/2026
Matt Miksic
Barclays
Sell
Reiterated
$64.00
-26.3%
05/18/2026
David Roman
Goldman Sachs
Buy
Maintained
$80.00
-7.9%
05/15/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$85.00
-2.2%
05/15/2026
Lee Hambright
Bernstein
Buy
Maintained
$77.00
-11.4%
05/15/2026
Unknown Analyst
Jefferies
Buy
Maintained
$112.00
+28.9%
05/14/2026
Unknown Analyst
Argus Research
Buy
Maintained
$86.00
-1%
05/05/2026
Brandon Vazquez
William Blair
Buy
Maintained
$59.00
-32.1%
05/01/2026
Suraj Kalia
Oppenheimer
Hold
Reiterated
-
-
02/13/2026
Patrick Wood
Morgan Stanley
Buy
Maintained
$75.00
-13.7%
02/13/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.70 / $0.61
+15.33%beat
Revenue / Est. (USD)
1.31B / 1.29B
+1.39%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.21B
1.26B
1.19B
1.31B
Cost of goods sold
477.90M
466.90M
441.60M
478.40M
Cost of revenue
477.90M
466.90M
441.60M
478.40M
Research and development expenses
157.50M
148.20M
145.30M
153.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
331.40M
321.50M
349.70M
358.70M
Operating expense
488.90M
469.70M
495.00M
511.70M
Total operating expenses
966.80M
936.60M
936.60M
990.10M
Operating income
242.50M
323.00M
255.30M
318.30M
Other non operating income
81.80M
-1.60M
-2.20M
-4.70M
EBT including unusual items
352.30M
340.70M
269.50M
317.50M
EBT excluding unusual items
352.30M
340.70M
269.50M
317.50M
Income tax expense
68.50M
73.40M
70.00M
68.40M
Effective tax rate
19.44%
21.54%
25.97%
21.54%
Other operating expenses
-
-
-
-
Net income
283.80M
267.30M
199.50M
249.10M
Net profit margin
23.47%
21.22%
16.74%
19.04%
Earnings per share
0.61
0.68
0.56
0.70
Interest and investment income
32.70M
23.50M
19.50M
16.90M
Interest expense
-4.70M
-4.20M
-3.10M
-3.00M
Net interest expenses
28.00M
19.30M
16.40M
13.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
306.10M
388.20M
322.40M
385.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps